Lisanti Capital Growth LLC Cuts Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Lisanti Capital Growth LLC cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 63.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 30,379 shares of the specialty pharmaceutical company’s stock after selling 52,175 shares during the quarter. Lisanti Capital Growth LLC’s holdings in ANI Pharmaceuticals were worth $2,398,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Illinois Municipal Retirement Fund increased its position in shares of ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock valued at $782,000 after buying an additional 145 shares in the last quarter. Amalgamated Bank increased its position in shares of ANI Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after buying an additional 154 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after buying an additional 198 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after buying an additional 200 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,772 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at approximately $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,312 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the transaction, the chief financial officer directly owned 185,543 shares in the company, valued at $14,008,496.50. This trade represents a 3.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 91,427 shares of company stock valued at $7,089,066 in the last three months. Company insiders own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Stock Down 0.1%

Shares of ANIP opened at $82.72 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 20.94 and a beta of 0.46. The stock has a 50 day moving average price of $77.90 and a 200 day moving average price of $80.11.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same period in the previous year, the business earned $1.70 earnings per share. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.